Adding to the current dialogue about paclitaxel in PAD, Dr.
Robert Lookstein shares commentary on Eluvia.
Eluvia has the lowest drug dose density among all peripheral paclitaxel-based technologies
Eluvia’s controlled drug delivery ensures that the majority of drug is transferred to the lesion rather than downstream
Eluvia has been shown to be endothelialized within 90 days post-implant2
1. Peter A. Schneider, MD, LINC 2017
2. Internal preclinical testing data on file.
Stay Up to Date
Receive emails about the latest drug-eluting technology news, innovations and events in your area.
Explore DE Resources
Get physician perspectives, clinical data sheets and other resources about drug-eluting innovations.